Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) EBT Margin: 2020-2023

Historic EBT Margin for Candel Therapeutics (CADL) over the last 4 years, with Dec 2023 value amounting to -119.24%.

  • Candel Therapeutics' EBT Margin rose 2528399.00% to -119.24% in Q4 2023 from the same period last year, while for Dec 2023 it was -1,299.23%, marking a year-over-year increase of 2688787.00%. This contributed to the annual value of -1,444.74% for FY2024, which is 14551.00% down from last year.
  • Per Candel Therapeutics' latest filing, its EBT Margin stood at -119.24% for Q4 2023, which was down 108.84% from 1,349.48% recorded in Q3 2023.
  • Candel Therapeutics' EBT Margin's 5-year high stood at 1,565.02% during Q1 2023, with a 5-year trough of -29,551.61% in Q1 2022.
  • For the 3-year period, Candel Therapeutics' EBT Margin averaged around -15,966.18%, with its median value being -21,075.81% (2021).
  • As far as peak fluctuations go, Candel Therapeutics' EBT Margin crashed by 1,720,968bps in 2021, and later soared by 3,111,664bps in 2023.
  • Candel Therapeutics' EBT Margin (Quarterly) stood at -19,600.00% in 2020, then plummeted by 540,323bps to -25,003.23% in 2021, then plummeted by 40,000bps to -25,403.23% in 2022, then soared by 2,528,399bps to -119.24% in 2023.
  • Its EBT Margin stands at -119.24% for Q4 2023, versus 1,349.48% for Q3 2023 and 1,517.08% for Q2 2023.